NantHealth Inc (NASDAQ:NH) has been given an average recommendation of “Hold” by the six ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $4.75.
Several equities research analysts have recently issued reports on the stock. BidaskClub upgraded shares of NantHealth from a “hold” rating to a “buy” rating in a research note on Friday, July 6th. Canaccord Genuity restated a “hold” rating on shares of NantHealth in a research note on Tuesday, July 3rd. ValuEngine upgraded shares of NantHealth from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd. Finally, Zacks Investment Research downgraded shares of NantHealth from a “buy” rating to a “hold” rating in a research note on Tuesday, August 21st.
Shares of NH stock opened at $1.46 on Wednesday. NantHealth has a 12 month low of $1.24 and a 12 month high of $4.05. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.48 and a current ratio of 1.50. The company has a market cap of $156.54 million, a price-to-earnings ratio of -1.30 and a beta of -0.04.
A hedge fund recently raised its stake in NantHealth stock. Dimensional Fund Advisors LP raised its stake in shares of NantHealth Inc (NASDAQ:NH) by 41.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 120,348 shares of the company’s stock after acquiring an additional 35,445 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.11% of NantHealth worth $398,000 as of its most recent filing with the SEC. 5.63% of the stock is owned by hedge funds and other institutional investors.
NantHealth Company Profile
NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.
Further Reading: Terms to Better Understand Call Options
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.